Every 8-K that Cardinal Health, Inc. (CAH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CAH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAH filings page.
Cardinal Health reported strong results for the fourth quarter and fiscal year ended June 30, 2026. Q4 revenue was $63.7 billion, up 6%. GAAP operating earnings rose 70% to $729 million, and GAAP diluted EPS increased 70% to $1.70. Non-GAAP operating earnings grew 30% to $935 million, and non-GAAP diluted EPS rose 40% to $2.91, including a one-time net benefit of $0.31 per share from IEEPA tariff refunds.
For fiscal 2026, revenue grew 14% to $254.2 billion. GAAP operating earnings were $2.6 billion and GAAP diluted EPS was $7.23. Non-GAAP operating earnings increased 30% to $3.6 billion, while non-GAAP diluted EPS rose 37% to $11.26, or $10.95 excluding the IEEPA tariff refund impact. Operating cash flow reached $5.2 billion and non-GAAP adjusted free cash flow was $5.0 billion. All five operating segments delivered double-digit profit growth on a non-GAAP basis.
Management issued fiscal 2027 non-GAAP EPS guidance of $12.40–$12.60, implying 13%–15% growth from adjusted 2026 results, and guided to $3.5–$4.0 billion in non-GAAP adjusted free cash flow. The company repurchased $1.4 billion of shares in fiscal 2026 and the board expanded share repurchase authorization by $5.0 billion to $6.4 billion. A quarterly dividend of $0.5158 per share was declared.
Cardinal Health, Inc. entered into a new unsecured $4.0 billion revolving credit facility on August 7, 2026 with a syndicate of banks and Wells Fargo Bank, National Association as Administrative Agent. The facility provides revolving credit access through August 7, 2031, and Cardinal Health may, subject to specified conditions, extend the termination date by up to two years.
The agreement includes customary representations, covenants and events of default, and requires Cardinal Health to maintain a Consolidated Net Leverage Ratio of no greater than 4.00 to 1.00 as of the last day of any fiscal quarter. The company plans to use the revolving credit facility for general corporate purposes.
On the same date, Cardinal Health terminated its $2.0 billion five-year revolving credit facility, its $1.0 billion 364-day revolving credit facility, and its $1.0 billion committed receivables sale program, incurring no termination penalties. The new credit agreement replaces these prior facilities.
Cardinal Health, Inc. appointed Anita Zielinski as Chief Accounting Officer, effective November 5, 2026. She will join as Senior Vice President Finance on September 16 and succeed Mary Scherer, who will remain Chief Accounting Officer through November 5, 2026.
Zielinski, 52, previously held senior finance and accounting roles at Baxter International and Sysco, and was a partner at Ernst & Young. Her compensation includes an annual base salary, annual cash bonus under the Management Incentive Plan, equity under the long-term incentive program, a $750,000 cash sign-on bonus, and an initial grant of time-vesting restricted share units with a grant date value of $1,000,000 that vest ratably over three years.
Cardinal Health reported a strong third quarter of fiscal 2026, combining solid growth with a notable non-cash charge. Revenue rose 11% to $60.9 billion versus the prior-year quarter. Non-GAAP operating earnings increased 18% to $956 million and non-GAAP diluted EPS grew 35% to $3.17, helped by stronger segment performance, a lower non-GAAP tax rate and a lower share count.
GAAP results were weaker as operating earnings fell 30% to $509 million and diluted EPS declined 20% to $1.69, driven mainly by a $184 million goodwill impairment in the Navista & ION reporting unit. The Pharmaceutical and Specialty Solutions segment posted 11% revenue growth and 18% profit growth, while the Other segment grew revenue 31% and profit 34%. Cardinal Health raised its fiscal 2026 non-GAAP EPS outlook to $10.70–$10.80, implying 30%–31% growth, and lifted adjusted free cash flow guidance to $3.3–$3.7 billion. The company also reduced debt, brought its leverage ratio to 3.0x and completed $1.0 billion of share repurchases year-to-date.
Cardinal Health, Inc. reported that on March 2, 2026, Senior Vice President and Chief Accounting Officer Mary Scherer notified the company of her intention to retire in February 2027. The company plans to conduct a search for her successor.
Scherer will continue serving as Chief Accounting Officer until a new executive is identified and onboarded to support a smooth transition in the company’s accounting leadership.
Cardinal Health, Inc. reported that it has released its financial results for the quarter ended December 31, 2025, via a news release furnished as Exhibit 99.1. These second-quarter results cover the company’s performance midway through its fiscal year.
The Chief Executive Officer and Chief Financial Officer are scheduled to host a webcast at 8:30 a.m. Eastern time on February 5, 2026 to discuss the quarterly results and the outlook for the fiscal year ending June 30, 2026. A slide presentation and an audio replay of the webcast will be available on the Investors page at ir.cardinalhealth.com.
Cardinal Health, Inc. reported that it has updated its previously issued fiscal year 2026 non-GAAP earnings per share outlook. This means the company has revised its internal expectations for how much profit per share it plans to generate, after adjusting for certain items.
The company also highlighted its upcoming appearance at the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 13 at 9:00 a.m. Pacific Standard Time. Additional details are provided in a news release issued on January 13, 2026 and attached as an exhibit.
Cardinal Health (CAH) reported voting results from its 2025 Annual Meeting. Shareholders elected 12 director nominees to serve until the 2026 Annual Meeting. The advisory vote on executive compensation passed with 168,382,554 votes For, 17,271,117 Against, and 1,513,298 Abstained.
Shareholders also ratified Ernst & Young LLP as the independent auditor for the fiscal year ending June 30, 2026, with 195,705,020 For, 12,253,800 Against, and 310,216 Abstained. Director elections included standard broker non-votes of 21,102,067 across proposals where applicable.
Cardinal Health, Inc. filed a current report to note that it has released financial results for the quarter ended September 30, 2025. The company issued a news release, which is furnished as Exhibit 99.1, summarizing its first-quarter performance.
The report also explains that the Chief Executive Officer and Chief Financial Officer will host a webcast at 8:30 a.m. Eastern time on October 30, 2025 to discuss the quarterly results and the outlook for the fiscal year ending June 30, 2026. A slide presentation and an audio replay of the webcast will be available on the Investors page of Cardinal Health’s website.
Cardinal Health, Inc. entered into a new 364-day credit agreement on October 7, 2025 with Bank of America, N.A. as administrative agent and a syndicate of lenders. The facility provides access to up to $1.0 billion of revolving credit through October 6, 2026 and replaces a similar 364-day agreement that expired from October 2024.
At the termination date, Cardinal Health may, subject to conditions in the agreement, convert any outstanding borrowings into non-revolving term loans that must be repaid one year later. The agreement includes customary representations, covenants and events of default, including a financial covenant requiring a consolidated net leverage ratio not greater than 3.75 to 1.00 as of the last day of any fiscal quarter.
The revolving credit facility may be used for general corporate purposes and backs the company’s commercial paper program. Participating financial institutions and their affiliates have previously provided, and may continue to provide, various banking and financial services to Cardinal Health for customary fees.
Cardinal Health, Inc. reported that several of its receivables financing subsidiaries and major banking partners entered into a First Amendment to an existing Fifth Amended and Restated Receivables Purchase Agreement originally dated September 1, 2023. The principal change is an extension of the term of this receivables financing facility to September 28, 2028, helping maintain access to funding backed by customer receivables.
Key counterparties include Wells Fargo, Liberty Street Funding, The Bank of Nova Scotia, PNC Bank, Bank of America, Victory Receivables Corporation and MUFG Bank. These institutions or their affiliates also provide other services to Cardinal Health, such as acting as dealers under its commercial paper program and participating in its $2.0 billion revolving credit facility.
Cardinal Health, Inc. filed an 8-K reporting execution of a Third Supplemental Indenture dated August 27, 2025, with The Bank of New York Mellon Trust Company, N.A., as trustee, and included forms of two note series: 4.500% Notes due 2030 and 5.150% Notes due 2035. The filing incorporates the original Indenture dated June 2, 2008, and includes legal opinions and consents from Cardinal Health's General Counsel and White & Case LLP, plus an embedded Inline XBRL cover page.
The disclosure documents appear to support issuance or amendment of long-term debt instruments by the company and provide legal and trustee documentation required for such securities. The filing is signed by Aaron E. Alt, Chief Financial Officer.
Cardinal Health, Inc. announced the sale of $1.0 billion of senior notes: $600,000,000 of 4.500% Notes due 2030 and $400,000,000 of 5.150% Notes due 2035, under an effective Form S-3ASR registration statement. The offering was made through an underwriting agreement dated August 13, 2025, with Goldman Sachs & Co. LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC serving as representatives of the underwriters. The disclosure references the registration statement number and notes that the cover page interactive data file is embedded in the Inline XBRL document. The Form 8-K is signed by Aaron E. Alt, Chief Financial Officer, and dated August 14, 2025.
Cardinal Health, Inc. disclosed that it has issued a news release reporting results for the quarter and fiscal year ended June 30, 2025. The company has scheduled a management webcast where the CEO and CFO will discuss those results and provide commentary on the outlook for the fiscal year ending June 30, 2026. The slide presentation and an audio replay will be available on the company’s Investors page.
The filing also reports that The Specialty Alliance, Cardinal Health’s multi-specialty management services organization, has entered into a definitive agreement to acquire Solaris Health. The two news releases are furnished as exhibits to the report.